This article was originally published in The Gray Sheet
Executive SummaryPlanned merger of Genzyme Tissue Repair, Genzyme Surgical Products and Biomatrix gains Federal Trade Commission anti-trust clearance, the companies announce June 26. Shareholder meetings are planned for the third quarter to finalize the deal. Initially anticipated to close in June, the merger has been delayed in order to respond to requests from the Securities and Exchange Commission regarding joint proxy statement
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.
The US FDA has finalized a new rule that updates a slew of agency regulations so sponsors no longer have to submit multiple paper copies of premarket submission applications. The agency says the rule could save companies millions of dollars.